Pephexia Therapeutics ApS: Financial statements 2025
CVR: 41319208
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
Pephexia Therapeutics ApS (CVR 41319208) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -179,735 and a net result of DKK -4,440,533 compared with DKK -5,320,870 the year before. Equity in the 2025 report amounted to DKK -19,747,345. The company had 4 employees in the financial year.
- Gross Profit
- DKK -179,735
- Profit/Loss
- DKK -4,440,533
- Equity
- DKK -19,747,345
- Total Assets
- DKK 2,016,227
- Employees
- 4
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | -180K | -4.4M | -19.7M | 4 |
| 2024 | - | -2.1M | -5.3M | -15.3M | 4 |
| 2023 | - | -3.2M | -5.4M | -12.6M | 3 |
| 2022 | - | -5.3M | -6.7M | -7.1M | 3 |
| 2021 | 626K | -4.7M | -4.5M | -2.7M | 0 |
Official annual report
How creditworthy is Pephexia Therapeutics ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
Pephexia Therapeutics ApS has published its annual report for 2024. Gross profit came to DKK -2,085,438, and the net result was DKK -5,320,870.
About Pephexia Therapeutics ApS
Pephexia Therapeutics ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2020. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Keld Fogtmann Fosgerau. The board consists of Anders Mørkeberg Hinsby (chair), Andrew Justin Stewart Coats, Keld Fogtmann Fosgerau and Mats Peter Blom. The company is owned by Fogtmann Fosgerau Holding ApS and Andrew Justin Stewart Coats. The company has 5 employees (2026). In 2025, the company reported a gross profit of DKK -179,735 and a net result of DKK -4,440,533 compared with DKK -5,320,870 the year before. Equity in the 2025 report amounted to DKK -19,747,345.